Diagnosis and management of overlap syndromes

Clinics in Liver Disease

Volumn 19, Issue 1, 2015, Pages 81-97

  Bunchorntavakul, Chalermrat ^a,b   Reddy, K Rajender ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b RANGSIT UNIVERSITY   (Thailand)

Author keywords

Autoimmune cholangitis; Autoimmune hepatitis; Autoimmune liver disease; Management; Overlap syndrome; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

IMMUNOGLOBULIN G4; IMMUNOSUPPRESSIVE AGENT; AUTOANTIBODY; CHOLAGOGUE; IMMUNOGLOBULIN; URSODEOXYCHOLIC ACID;

AUTOIMMUNE HEPATITIS; CHOLANGITIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; HUMAN; IMMUNOGLOBULIN G4 ASSOCIATED CHOLANGITIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; OVERLAP SYNDROME; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; RECURRENT DISEASE; REVIEW; TOXIC HEPATITIS; TREATMENT RESPONSE; BLOOD; CHOLANGITIS, SCLEROSING; DISEASE COURSE; HEPATITIS, AUTOIMMUNE; LIVER CIRRHOSIS, BILIARY; SYNDROME;

AUTOANTIBODIES; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; SYNDROME; URSODEOXYCHOLIC ACID;

EID: 84927583131     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2014.09.005     Document Type: Review

References (70)

1. Trivedi P.J., Hirschfield G.M. Review article: overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther 2012, 36(6):517-533.
2. Manns M.P., Czaja A.J., Gorham J.D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010, 51(6):2193-2213.
3. Chapman R., Fevery J., Kalloo A., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010, 51(2):660-678.
4. Lindor K.D., Gershwin M.E., Poupon R., et al. Primary biliary cirrhosis. Hepatology 2009, 50(1):291-308.
5. Czaja A.J. Cholestatic phenotypes of autoimmune hepatitis. Clin Gastroenterol Hepatol 2013, 12(9):1430-1438.
6. European Association for the Study of the Liver EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51(2):237-267.
7. Czaja A.J. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol 2013, 27(7):417-423.
8. Haldar D., Hirschfield G.M. Overlap syndrome: a real syndrome?. Clin Liver Dis 2014, 3(3):43-47.
9. Czaja A.J. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci 2013, 58(2):326-343.
10. Burak K.W., Urbanski S.J., Swain M.G. Acase of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases. Dig Dis Sci 2001, 46(9):2043-2047.
11. Rubel L.R., Seeff L.B., Patel V. Primary biliary cirrhosis-primary sclerosing cholangitis overlap syndrome. Arch Pathol Lab Med 1984, 108(5):360-361.
12. Jeevagan A. Overlap of primary biliary cirrhosis and primary sclerosing cholangitis - a rare coincidence or a new syndrome. Int J Gen Med 2010, 3:143-146.
13. Kingham J.G., Abbasi A. Co-existence of primary biliary cirrhosis and primary sclerosing cholangitis: a rare overlap syndrome put in perspective. Eur J Gastroenterol Hepatol 2005, 17(10):1077-1080.
14. Alvarez F., Berg P.A., Bianchi F.B., et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31(5):929-938.
15. Hennes E.M., Zeniya M., Czaja A.J., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48(1):169-176.
16. Wiegard C., Schramm C., Lohse A.W. Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future. Semin Liver Dis 2009, 29(3):254-261.
17. Boberg K.M., Chapman R.W., Hirschfield G.M., et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011, 54(2):374-385.
18. Czaja A. Overlap syndromes. Clin Liver Dis 2014, 3(1):2-5.
19. Bangarulingam S.Y., Gossard A.A., Petersen B.T., et al. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol 2009, 104(4):855-860.
20. Bunchorntavakul C., Tanwandee T., Charatcharoenwitthaya P., et al. Primary sclerosing cholangitis: from pathogenesis to medical management. NA J Med Sci 2012, 5(2):82-93.
21. Boberg K.M. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002, 6(3):635-647.
22. Kim W.R., Lindor K.D., Locke G.R., et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000, 119(6):1631-1636.
23. Prince M.I., James O.F. The epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003, 7(4):795-819.
24. Chazouilleres O., Wendum D., Serfaty L., et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28(2):296-301.
25. Czaja A.J. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998, 28(2):360-365.
26. Joshi S., Cauch-Dudek K., Wanless I.R., et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002, 35(2):409-413.
27. Metcalf J.V., Mitchison H.C., Palmer J.M., et al. Natural history of early primary biliary cirrhosis. Lancet 1996, 348(9039):1399-1402.
28. Czaja A.J., Carpenter H.A., Manns M.P. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993, 105(5):1522-1528.
29. Nakamura M., Kondo H., Mori T., et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007, 45(1):118-127.
30. Kuiper E.M., Zondervan P.E., van Buuren H.R. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010, 8(6):530-534.
31. Poupon R., Chazouilleres O., Corpechot C., et al. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006, 44(1):85-90.
32. Horsmans Y., Piret A., Brenard R., et al. Autoimmune chronic active hepatitis responsive to immunosuppressive therapy evolving into a typical primary biliary cirrhosis syndrome: a case report. J Hepatol 1994, 21(2):194-198.
33. Lindgren S., Glaumann H., Almer S., et al. Transitions between variant forms of primary biliary cirrhosis during long-term follow-up. Eur J Intern Med 2009, 20(4):398-402.
34. Suzuki Y., Arase Y., Ikeda K., et al. Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome. JGastroenterol Hepatol 2004, 19(6):699-706.
35. Silveira M.G., Talwalkar J.A., Angulo P., et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007, 102(6):1244-1250.
36. Corpechot C., Carrat F., Poupon R., et al. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002, 122(3):652-658.
37. Huet P.M., Vincent C., Deslaurier J., et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology 2008, 135(5):1552-1560.
38. Lohse A.W., zum Buschenfelde K.H., Franz B., et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999, 29(4):1078-1084.
39. Chazouilleres O., Wendum D., Serfaty L., et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006, 44(2):400-406.
40. Baven-Pronk A.M., Coenraad M.J., van Buuren H.R., et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011, 34(3):335-343.
41. Duclos-Vallee J.C., Hadengue A., Ganne-Carrie N., et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A. Dig Dis Sci 1995, 40(5):1069-1073.
42. Gregorio G.V., Portmann B., Karani J., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001, 33(3):544-553.
43. McNair A.N., Moloney M., Portmann B.C., et al. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998, 93(5):777-784.
44. van Buuren H.R., van Hoogstraten H.J., Terkivatan T., et al. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000, 33(4):543-548.
45. Abdo A.A., Bain V.G., Kichian K., et al. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002, 36(6):1393-1399.
46. Floreani A., Rizzotto E.R., Ferrara F., et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005, 100(7):1516-1522.
47. Kaya M., Angulo P., Lindor K.D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000, 33(4):537-542.
48. Lewin M., Vilgrain V., Ozenne V., et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009, 50(2):528-537.
49. Abdalian R., Dhar P., Jhaveri K., et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008, 47(3):949-957.
50. Perdigoto R., Carpenter H.A., Czaja A.J. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992, 14(2-3):325-331.
51. Lindor K.D., Kowdley K.V., Luketic V.A., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50(3):808-814.
52. Al-Chalabi T., Portmann B.C., Bernal W., et al. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008, 28(2):209-220.
53. Olsson R., Glaumann H., Almer S., et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med 2009, 20(2):190-196.
54. Luth S., Kanzler S., Frenzel C., et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol 2009, 43(1):75-80.
55. Bunchorntavakul C., Reddy K.R. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012, 16(2):331-346.
56. Gheorghe L., Iacob S., Gheorghe C., et al. Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease. Eur J Gastroenterol Hepatol 2004, 16(6):585-592.
57. Muratori L., Cassani F., Pappas G., et al. The hepatitic/cholestatic "overlap" syndrome: an Italian experience. Autoimmunity 2002, 35(8):565-568.
58. Czaja A.J., Carpenter H.A., Santrach P.J., et al. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000, 31(6):1231-1238.
59. Czaja A.J., Carpenter H.A. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003, 23(2):116-123.
60. Ghazale A., Chari S.T., Zhang L., et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008, 134(3):706-715.
61. Mayo M.J. Cholestatic liver disease overlap syndromes. Clin Liver Dis 2013, 17(2):243-253.
62. Silveira M.G. IgG4-associated cholangitis. Clin Liver Dis 2013, 17(2):255-268.
63. Alswat K., Al-Harthy N., Mazrani W., et al. The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol 2012, 107(1):56-63.
64. Mendes F.D., Jorgensen R., Keach J., et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006, 101(9):2070-2075.
65. Czaja A.J. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011, 56(4):958-976.
66. Bhamidimarri K.R., Schiff E. Drug-induced cholestasis. Clin Liver Dis 2013, 17(4):519-531. vii.
67. Bunchorntavakul C., Reddy K.R. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther 2013, 37(1):3-17.
68. Ilyas J.A., O'Mahony C.A., Vierling J.M. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol 2011, 25(6):765-782.
69. Bhanji R.A., Mason A.L., Girgis S., et al. Liver transplantation for overlap syndromes of autoimmune liver diseases. Liver Int 2013, 33(2):210-219.
70. Yamashiki N., Sugawara Y., Tamura S., et al. Living-donor liver transplantation for autoimmune hepatitis and autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. Hepatol Res 2012, 42(10):1016-1023.